Central retinal thickness μm (CRT) change at 1 year The aim of treatment is to reduce central retinal thickness so thinner is better. · people with neovascular age‐related macular degeneration
1 finding from 1 review
QoL · people with neovascular age‐related macular degeneration
1 finding from 1 review
Number of injections at 1 year · people with neovascular age‐related macular degeneration
1 finding from 1 review
Cost of treatment per person at 1 year · people with neovascular age‐related macular degeneration
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with endophthalmitis · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in endophthalmitis (ocular adverse event) compared with monthly injections (low certainty).
1 finding from 1 review
Change in BCVA at 1 year (ETDRS letters score, the higher the score the better) · people with neovascular age‐related macular degeneration
1 finding from 1 review
Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration
Extended‐fixed showed no clear difference in gain of ≥ 15 letters visual acuity at 1 year compared with monthly injections (moderate certainty).
1 finding from 1 review
BCVA: loss of 15 or more ETDRS letters · people with diabetic retinopathy
Extended targeted PRP showed no clear difference in BCVA: loss of 15 or more ETDRS letters: compared with standard PRP (low certainty).
1 finding from 1 review
BCVA: gain of 15 or more ETDRS letters · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression of DR ‐ not reported · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Regression of PDR · people with diabetic retinopathy
Extended targeted PRP showed no clear difference in regression of PDR compared with standard PRP (low certainty).
1 finding from 1 review
Pain during laser treatment ‐ not reported · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vision‐related QoL ‐ not reported · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetic retinopathy
It is very uncertain whether extended targeted PRP changes adverse events compared with standard PRP (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low